Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

ABSTRACT:

Background

While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease.

Patients and methods

We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been

SUBMITTER: Ponzoni M 

PROVIDER: S-EPMC3905778 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature